Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 1/20 | 0.49 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8924266 | 0.88 | CTRC (0.59) | CTRCLMNAL3MBTL1BCHEPPARA | |
| SCHEMBL9799651 | 0.88 | CTRC (0.59) | CTRCLMNAL3MBTL1BCHEPPARA | |
| SCHEMBL7775204 | 0.88 | CTRC (0.59) | CTRCLMNAL3MBTL1BCHEPPARA | |
| SCHEMBL13029242 | 0.86 | NR5A1 (0.43) | L3MBTL1LTA4HPLA2G2A | |
| Monobenzone SCHEMBL10867013 | 0.83 | CTRC (0.57) | CTRCLMNAL3MBTL1BCHEPPARA | |
| SCHEMBL10000689 | 0.83 | NR5A1 (0.43) | LMNAL3MBTL1GPR88LTA4H | |
| SCHEMBL13068574 | 0.82 | APP (0.37) | GPR88 | |
| SCHEMBL10000688 | 0.82 | GPR88 (0.36) | PPARAGPR88 | |
| SCHEMBL9405922 | 0.81 | GSTP1 (0.46) | GSTP1ARLTA4HEPHX2PLA2G10 | |
| SCHEMBL10624624 | 0.80 | NR5A1 (0.48) | CTRCLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101095-B2 | Antiferroelectric orthoconic liquid crystalline material with long pitch and the method of its preparation | WOJSKOWA AKADEMIA TECHNICZNA IM. JAROSLAWA DABROWSKIEGO (PL) | 2012-01-24 | — | — | US | disclosed |
| US-20100258765-A1 | ANTIFERROELECTRIC ORTHOCONIC LIQUID CRYSTALLINE MATERIAL WITH LONG PITCH AND THE METHOD OF ITS PREPARATION | WOJSKOWA AKADEMIA TECHNICZNA IM. JAROSLAWA DABROWSKIEGO (PL) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100258765-A1 | ANTIFERROELECTRIC ORTHOCONIC LIQUID CRYSTALLINE MATERIAL WITH LONG PITCH AND THE METHOD OF ITS PREPARATION | CRY2, PAX2, CXXC5 | CTRC 858/4885GSTP1 3654/4885LMNA 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.